Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546077 | 0.88 | CYP1A2 (0.54) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL869422 | 0.88 | CYP1A2 (0.54) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL11050149 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL25754255 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP2A6SIGMAR1HTR2AHTR2C | |
| SCHEMBL16594922 | 0.82 | KDM4E (0.49) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL16594736 | 0.82 | KDM4E (0.49) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL16594921 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP2A6SIGMAR1HTR2AHTR2C | |
| SCHEMBL25753182 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP2A6SIGMAR1HTR2AHTR2C | |
| SCHEMBL16594734 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP2A6SIGMAR1HTR2AHTR2C | |
| SCHEMBL19509057 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-4459186-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP1A2 420/4885CYP2A6 1153/4885SIGMAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.